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Summary
Spinal muscular atrophy (SMA) is a common autosomal
recessive neuromuscular disorder characterized by de-
generation of motor neurons of the spinal cord. The
survival motor neuron gene (SMN) has been recognized
as the disease-causing gene. SMN is duplicated, and the
almost identical copy gene (SMNc) remains functional
in patients with SMA. The expression level of SMNc is
tightly correlated with the clinical severity of the disease.
Here, we define the transcription initiation site, delineate
the region containing promoter activity, and analyze the
sequence of the promoter region of both SMN and
SMNc. We show that the promoter sequence and activity
of the two genes are quasi identical, providing strong
evidence for similar transcription regulation of the two
genes. Therefore, the difference in the level of protein
encoded by SMN and SMNc is the result of either dif-
ferent regulatory region(s) further apart or different
posttranscriptional regulation. Interestingly, sequence
analysis of the promoter region revealed several consen-
sus binding sites for transcription factors. Therefore, the
identification of transcription factors involved in the reg-
ulation of SMNc gene expression may lead to attractive
strategies for therapy in SMA.
Introduction
Spinal muscular atrophy (SMA) is a common autosomal
recessive neuromuscular disorder characterized by de-
generation of motor neurons of the spinal cord. Three
different forms of childhood SMA have been recognized
on the basis of age at onset and clinical course:Werdnig-
Hoffmann disease, the most severe form (type I; MIM
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253300); the intermediate form (type II; MIM 253550);
and Kugelberg-Welander disease, the mildest form (type
III; MIM 253400) (Munsat 1991). The survival motor
neuron gene (SMN) has been recognized as the disease-
causing gene (Lefebvre et al. 1995). SMN is duplicated
with a highly homologous copy gene (SMNc) (Lefebvre
et al. 1995; Burglen et al. 1996). Ninety-five percent of
healthy individuals carry both SMN and SMNc, whereas
5% carry SMN only, as determined by exon 7 analysis.
In SMA, 95% of patients carry homozygous deletion or
conversion events of SMN exon 7, and the other 5%
carry intragenic mutations within SMN (reviewed in
Melki 1997). SMN encodes a protein located within a
novel nuclear structure called “gems,” for “gemini of
coiled bodies,” and that interacts with components of
the spliceosomal complex, suggesting that SMN has an
important role in RNA processing (Liu and Dreyfuss
1996; Fischer et al. 1997; Liu et al. 1997). Protein anal-
ysis revealed that both genes are expressed. Tight cor-
relation between the amount of protein encoded by
SMNc—which remains functional in patients—and the
clinical severity of the disease has been demonstrated in
patients with SMA (Coovert et al. 1997; Lefebvre et al.
1997). Importantly, the low level of SMNc protein in
SMA tissues in comparison to the SMN protein level in
control tissues suggested that the expression or the sta-
bility of SMN and SMNc gene products may be different
(Lefebvre et al. 1997). These data prompted us to com-
pare the promoter activity and sequence of both genes
and to define the elements that regulate the expression
of SMN and SMNc.
Material and Methods
Primer Extension Analysis
Two 30-mer oligonucleotides complementary to the
sequence of SMN exon 1 from position 227 to 198
(5′–CCG GAA CAG CAC GGA ATC CTC CTG CTC
CGG–3′, PE1) and from position 222 to 192
(5′–ACA GCA CGG AAT CCT CCT GCT CCG GGA
CGC–3′, PE7) (Lefebvre et al. 1995) were synthesized
and end-labeled with [32P]-gATP by use of T4 polynu-
cleotide kinase (Sambrook et al. 1989). Unincorporated
1366 Am. J. Hum. Genet. 64:1365–1370, 1999
nucleoside triphosphates were removed after centrifu-
gation through a Sephadex G50 column. A total of 20
mg of total RNA from HeLa cells was hybridized with
the labeled primers at 40C for 12 h. After the sample
cooled to room temperature (22C), avian myeloblas-
tosis virus reverse transcriptase (Boehringer Mannheim)
was added, and the samples were incubated at 42C for
1 h. The extension products were then separated on an
8 M urea, 6% polyacrylamide gel. Total RNA was ex-
tracted from HeLa cells by use of the Trizol procedure
(Gibco/BRL). For molecular weight markers, the se-
quencing reaction was primed, with an oligonucleotide
chosen in the 5′-upstream region of SMN, by use of the
sequenase method (Sambrook et al. 1989), with a 54PBL
clone serving as template.
Cloning, Construction of Plasmids, and DNA
Sequencing
Genomic clones containing the first exon and flanking
regions of SMN (L-132) and SMNc (121-B) were iso-
lated from a FIX II phage library constructed from YAC
clones containing SMN (YAC clone 595C11) and SMNc
(YAC clone 121B8), respectively (Melki et al. 1994; Le-
febvre et al. 1995; Burglen et al. 1996). By use of re-
striction mapping and Southern blot analyses, we iden-
tified a 2-kb HindIII-SacII restriction fragment spanning
the 5′-upstream region of each gene and subcloned it
into pUC18 for further characterization. DNA sequenc-
ing reactions were performed, by use of the dideoxyn-
ucleotide chain–termination method, on double-strand
plasmid DNA with oligonucleotides corresponding to
the first exon sequence and were analyzed on an ABI
model 373A DNA automated sequencer. From the ob-
tained sequence, a series of oligonucleotide primers was
generated to sequence the entire 2-kbHindIII-SacII frag-
ment. Search for consensus DNA elements involved in
regulating gene expression was performedwith the Tran-
scription Element Search (TESS) and Signal Scan
softwares.
To determine whether the cloned sequences contained
promoter activity, we cloned the 2-kb HindIII-SacII 5′-
upstream region of both genes into the polylinker site
of the reporter plasmid pBLCAT6, which contains the
chloramphenicol acetyltransferase (CAT) gene as a re-
porter gene (Boshart et al. 1992). Plasmids 54PBL and
121PBL carry the SMN and SMNc 5′-upstream regions,
respectively. Fusion constructs containing deleted frag-
ments derived from the 2-kb HindIII-SacII insert were
generated. The 870-bp FokI-SacII, 530-bp DraI-SacII,
or 290-bp PstI-SacII fragment was cloned into the
polylinker site of the pBLCAT6 plasmid vector to gen-
erate 54Fok2, 54SsD5, or 5Ps1 plasmid clones, re-
spectively.
CAT Assays
HeLa cells were maintained in Dulbecco’s modified
Eagle medium (DMEM) supplemented with 5% fetal
calf serum (FCS) and plated at a density of 105 per well
in a 48-well tissue culture dish (Costar) 3 h prior to
transfection. A total of 1.8 mg of plasmid DNA was
coprecipitated with calcium phosphate (Foulkes et al.
1991). For each assay, 0.4 mg of pCH110 b-galactosidase
expression plasmid (Pharmacia) was cotransfected for
normalization of efficiency. A total of 200 ml of the pre-
cipitate was applied per well containing 2 ml of the
appropriate culture medium. After 24 h, cells were
washed with DMEM without FCS; then fresh DMEM
supplemented with 5% FCS was added for 24 h. Cells
were harvested for CAT assays 48 h posttransfection.
Cells were dislodged by scraping in PBS, and extracts
were prepared in 100 ml of TEN (50 mM Tris-HCl at
7.4 pH, 1 mM EDTA, and 150 mM NaCl) by use of
three freeze-thaw cycles. Extracts were centrifuged at
12,000 rpm at 4C for 5 min, and the resulting super-
natants were stored at 80C. CAT assays were per-
formed on 20 ml of extracts with a CAT-ELISA kit (Boeh-
ringer Mannheim) according to the instructions of the
manufacturer. CAT concentrations were normalized ac-
cording to the b-galactosidase activities originating from
the cotransfected internal control plasmid pCH110
(Sambrook et al. 1989). In addition, promoterless con-
struct pBLCAT6 was used as a negative control for each
transfection experiment.
Results
Delineating the Transcription Initiation Site and
Promoter Region
The transcription initiation site had remained un-
known until now, and the longest 5′ untranslated region
was 33 bp in length (Lefebvre et al. 1995). Primer ex-
tension analysis was used to identify the transcription
initiation site. Oligonucleotides complementary to the
sequence of exon 1 from position 227 to 198 (PE1)
and from position 222 to 192 (PE7) were used for
cDNA synthesis from total RNA of HeLa cells. The ex-
tension products were then separated on a denaturing
polyacrylamide gel, and a 229-bp product from the PE1
primer was detected (fig. 1). Similar results were ob-
tained by using PE7 as a primer, implying that SMN
transcripts initiate at position1 (data not shown). This
site is located 162 bp upstream of the first ATG.
To determine whether the region upstream from the
transcription initiation site contained promoter activity,
we fused the 2-kb HindIII-SacII fragments correspond-
ing to SMN and SMNc to the bacterial CAT gene, pro-
ducing the plasmids 54PBL and 121 PBL, respectively
(figs. 2 and 3). The resulting plasmids were transiently
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Figure 1 Primer extension analysis. PE1 primer was hybridized
to 20 mg of total RNA from HeLa cells. A sequencing reaction of a
known template was used as molecular size marker. The arrow indi-
cates the specific band corresponding to the extended product. A
smaller but weaker band was not consistently found, suggesting that
this is a nonspecific product.
Figure 2 A, CAT reporter constructs. The arrow indicates the
transcription start site identified by primer extension analysis. A prom-
oterless CAT plasmid (PBL) was included to estimate the background
activity of the plasmid. B, Comparative activity of SMN (54PBL) and
SMNc (121PBL) gene promoters. Relative CAT activities were cal-
culated by comparing the activities of the transfected CAT plasmids
(pgCAT/ml) with b-galactosidase activities of the cotransfected
PCH110 plasmid (pgCAT/b-gal). Values are presented as mean SEM
of 20 transfection experiments. C, Comparison of relative CAT activ-
ities of successive deletion constructs. Transfection experiments with
deleted constructs allowed the identification of the minimal SMN pro-
moter region between PstI and SacII restriction sites (5Ps1). Relative
CAT activities are calculated as indicated above and presented as mean
 SEM of six transfection experiments. H  HindIII, S  SacII, P 
PstI, D  DraI, and F  FokI.
transfected into HeLa cells with calcium phosphate, and
the cell lysate was assayed for CAT activity. As shown
in figure 2, the 5′-upstream regions from position
1,890 to 152 of SMN (54PBL) and SMNc (121PBL)
direct expression of the CAT gene. This demonstrates
that the 1,890-bp region 5′ upstream of the transcription
initiation site contains promoter activity. There was no
significant difference in CAT activity between SMN and
SMNc gene promoters (fig. 2).
Deletion constructs were used to further delineate the
location of the minimal SMN promoter region (fig. 2).
They were obtained after double digestion of the 2-kb
HindIII-SacII insert withHindIII and FokI, PstI, orDraI
restriction enzymes, then ligation of the insert to the
polylinker site of pBLCAT6, producing the plasmids
54Fok2 (767 to 152, 919 bp in length), 54SsD5
(410 to 152, 562 bp), and 5Ps1 (143 to 152,
295 bp), respectively (fig. 2). A fusion construct con-
taining the sequence from143 to152 of SMN (5Ps1)
can direct expression of the CAT gene (fig. 2). Since the
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Figure 3 DNA sequence spanning the promoter region of SMN
and SMNc. Italic letters indicate the (CA) repeats corresponding to
the polymorphic C272 marker. Consensus binding motifs of transcrip-
tion factors and a putative TATA box are underlined. Small vertical
arrows indicate restriction enzyme sites that have been used for gen-
erating deleted constructs (GenBank accession number AF092925).
transcription initiation site is located at position 1,
these data strongly suggest that the minimal SMN pro-
moter sequence is located downstream of position143.
Plasmid constructs retaining or not retaining the dinu-
cleotide (CA) repeats of the C272 polymorphic marker
(plasmid clones 54SsD5 and 5Ps1, respectively) (figs. 2
and 3) exhibit similar promoter activity. Finally, the de-
letion of 1,123 bp from the 5′ end of 54PBL (plasmid
clone 54Fok2) resulted in a 5.3-fold increased activity
with respect to that of the full-length construct (plasmid
clone 54PBL), possibly because of the deletion of a cis-
regulating element(s) that represses the expression of
SMN in HeLa cells (fig. 2).
Promoter Sequences of SMN and SMNc Contain
Several Consensus DNA Elements Involved in
Regulating Gene Expression
The delineation of the transcription initiation site and
the definition of the region required for promoter activity
enabled us to characterize the sequence involved in the
regulation of SMN and SMNc (fig. 3). Comparative se-
quence analysis showed no sequence difference between
the 5′-upstream regions of SMN and SMNc, except for
the number of (CA) repeats corresponding to the poly-
morphic marker C272 (D5F150S1 and S2) (Melki et al.
1994), which were 26 and 21 in the SMN and SMNc
genes analyzed, respectively (data not shown). A puta-
tive TATA box was found in the minimal promoter re-
gion at position 49 from the transcription initiation
site, which is more upstream than found in many eu-
karyotic genes (Lodish et al. 1995). We searched for
other putative regulatory elements with TESS and Signal
Scan software programs and identified several well-con-
served consensus sequences corresponding to binding
sites for transcription factors. Consensus binding sites
for AP-1 and cAMP-responsive element (CRE) were
found at positions 1,704, 1,465, and 741, sug-
gesting that transcription factors such as c-Fos, c-Jun,
and Cre-binding protein (CREB) may regulate SMN
gene expression (Sassone-Corsi 1995). Interestingly, the
deletion of 1,123 bp from the 5′ end of the full-length
construct, removing an AP-1 site and a CRE site (at
positions 1,704 and 1,465, respectively), resulted in
a 5.3-fold increased activity (figs. 2 and 3). Transcription
factors bound to AP-1 or CRE could therefore represent
good candidate elements for inhibiting SMN expression
in HeLa cells. Several consensus binding sites for tran-
scription factors involved or associated with differenti-
ation and/or survival of neuronal cells—such as AP-2
(Mitchell et al. 1991), E2F-1 (Dupont et al. 1998),
GATA-2 (Meng et al. 1997), HNF-3 (Jacob et al. 1997),
N-Oct-3 (Schreider et al. 1993), and YY1 (Zambrano
et al. 1997)—were found (fig. 3). We also identified the
presence of an interferon gene regulatory element (IRE,
AAAAAGGAAAGGA) (Goodbourn et al. 1985) in the
minimal promoter region of SMN, 65 nucleotides up-
stream of the transcription initiation site (fig. 3).
Discussion
By studying 2 kb of the 5′-upstream regions of SMN
and SMNc, we were able to identify the promoter
regions and show that the promoter sequence and ac-
tivity of the two genes are quasi identical. SMN has been
recognized as the disease-causing gene (Lefebvre et al.
1995). SMN is duplicated with a highly homologous
copy gene (SMNc) (Lefebvre et al. 1995; Burglen et al.
1996), which remains expressed in patients. Importantly,
the low level of SMNc protein in SMA tissues in com-
parison to the SMN protein level in control tissues sug-
gests that SMN and SMNc gene products differ in ex-
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pression or stability (Coovert et al. 1997; Lefebvre et al.
1997). The present study provides strong evidence for
similar transcriptional regulation of both genes. There-
fore, the difference in the levels of protein encoded by
SMN and SMNc is the result of either different regu-
latory regions further apart or different posttranscrip-
tional regulation. An alternative splicing of exon 7 has
been found to be specific for SMNc (Lefebvre et al.
1995). Studying the role of this splicing event in the
stability of SMNc transcripts retaining or lacking exon
7 and the corresponding proteins should contribute to
elucidating the regulation of SMN and SMNc
expression.
Tight correlation between the level of protein encoded
by SMNc and the clinical severity of the disease has been
established, suggesting that SMNc can be regarded as a
modifying gene in SMA (Coovert et al. 1997; Lefebvre
et al. 1997). Therefore, identification of transcription
factors involved in the regulation of SMNc gene ex-
pression may lead to attractive strategies for therapy in
SMA. DNA sequence analysis of SMN and SMNc pro-
moters revealed several potential binding sites for tran-
scription factors that may be involved in SMN and
SMNc gene regulation. The presence of consensus bind-
ing sites for transcription factors AP-1 and CRE suggests
that SMN gene expression may be regulated by, and
possibly involved in, the response to signal transduction
pathways and cell cycle regulation. SMN protein has
been found to be highly expressed in neurons of re-
stricted areas, includingmotor neurons of the spinal cord
(Battaglia et al. 1997; Lefebvre et al. 1997). This suggests
that the neuronal expression pattern of SMN may be
the result of regulation by cell-specific transcription fac-
tors. The present study has led to the identification of
putative binding sites for transcription factors such as
AP-2, GATA-2, HNF-3, N-Oct-3, and YY1, which are
involved or associated with differentiation and/or with
survival neuronal cells (Mitchell et al. 1991; Schreider
et al. 1993; Jacob et al. 1997; Meng et al. 1997; Zam-
brano et al. 1997; Dupont et al. 1998). Further char-
acterization of the SMN promoter in neuronal cell lines
should allow the identification of transcription factors
driving SMN gene expression in neurons.
Another characteristic of the SMN promoter is the
presence of a (CA) repeat located at position 307 and
corresponding to the C272 polymorphic marker (Melki
et al. 1994). Since the (CA) repeats possess the potential
to adopt Z-DNA conformation in vitro, it has been spec-
ulated that its presence in the 5′ flanking region of genes
might confer regulatory effects on gene transcription
(Tripathi and Brahmachari 1991). In the present study,
we found that sequences with and without the (CA)
repeats exhibit similar promoter activity. In addition, the
difference in length of the (CA) repeats between SMN
and SMNc gene promoters does not result in significant
differences in promoter activity. Therefore, these data
indicate that the number of (CA) repeats in the SMN
and SMNc promoter regions does not exert regulatory
effects on gene transcription in vitro.
More interestingly, we identified the presence of an
IRE in the minimal promoter region of SMN. An IRE
is required for b-interferon induction in response to viral
infection or to double-stranded RNA poly(I)-poly(C)
(Goodbourn et al. 1985). Studies are in progress to de-
termine the contribution of the IRE consensus sequence
to the regulation of SMN and SMNc gene transcription.
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